Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115763 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Exacerbation of neuropsychiatric symptoms in an adult male with influenza A virus treated with oseltamivir.
Ment Health Clin
December 2024
PGY-2 Psychiatric Pharmacy Resident, Mercy Health St. Charles Hospital Oregon, Ohio,
Oseltamivir (Tamiflu) package labeling has a warning for neuropsychiatric adverse events (NPAE), most commonly in children and adolescents, especially males. There are several case reports of NPAE in adults treated with oseltamivir, but few document patients with preexisting neuropsychiatric conditions without additional contributing factors. This case report describes a 22-year-old male with a history of bipolar disorder, depression, and attention-deficit/hyperactivity disorder who had been stable on his medication regimen before experiencing sudden worsening of symptoms after the initiation of oseltamivir.
View Article and Find Full Text PDFBackground: Influenza virus is a widespread pathogen that poses significant health risks to humans. Oseltamivir and Baloxavir Marboxil are commonly utilized medications for both treating and preventing influenza infections. Despite their widespread use, there remains a need to thoroughly investigate their safety profiles and potential adverse reactions.
View Article and Find Full Text PDFThe real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system.
Front Pharmacol
July 2024
Department of Pharmacy, People's Hospital of Zhongjiang County, Deyang, China.
Background: Oseltamivir and baloxavir marboxil are the two primary oral drugs approved by the Food and Drug Administration (FDA) for treating influenza. Limited real-world evidence exists on their adverse events in children. The purpose of this study was to explore the adverse event (AE) profiles of oseltamivir and baloxavir marboxil in children based on the U.
View Article and Find Full Text PDFSafety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.
BMC Infect Dis
May 2024
Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, 10# Zhenhai Road, Xiamen, China.
Article Synopsis
- The study evaluates the safety profiles of two influenza treatments: Oseltamivir and Baloxavir Marboxil, by analyzing adverse events (AEs) reported to the FDA from 2004 to 2022.
- A comprehensive assessment of 15,104 Oseltamivir cases and 1,594 Baloxavir Marboxil cases identified common and drug-specific AEs, emphasizing significant findings like appendicolith and fulminant hepatitis for Oseltamivir, and Melaena for Baloxavir.
- The research highlights the importance of understanding these AEs to provide essential clinical references in light of limited influenza treatment options.
Psychotic Agitation in a Patient with COVID-19: Pathogenesis or Iatrogenesis?
Psychiatry Clin Psychopharmacol
June 2021
Department of Psychiatry, Bakirkoy Prof Mazhar Osman Training and Research Hospital for Psychiatry, Neurology, and Neurosurgery, Istanbul, Turkey.
Article Synopsis
- The CNS effects of SARS-CoV-2 infection and the neuropsychiatric impact of COVID-19 treatments remain unclear.
- A case study of a 43-year-old woman revealed new-onset psychotic symptoms, possibly linked to either the virus or her medications.
- This highlights the need for careful neuropsychiatric monitoring in COVID-19 patients and awareness of the safety profiles of treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!